TG Therapeutics announced positive Phase 3 ENHANCE trial results demonstrating that a single 600 mg infusion of BRIUMVI for relapsing multiple sclerosis (RMS) provides bioequivalent drug exposure compared to the current two-dose initiation regimen. This new dosing could simplify treatment by eliminating the need for a second infusion two weeks later, potentially speeding up therapy start and easing scheduling at infusion centers. Safety and efficacy were consistent with previous studies, with no new safety concerns. TG Therapeutics plans to submit a supplemental Biologics License Application (BLA) in the second half of 2026 to seek approval for this streamlined dosing.
TG Therapeutics remains a "Strong Buy" as its drug BRIUMVI shows strong market momentum with 63% year-over-year sales growth in Q1. The company raised its 2026 BRIUMVI sales guidance to $885–$900 million, supported by successful Phase 3 trial results...
TG Therapeutics announced that its CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 3, 2026. The event will be webcast live on the company's website. TG Therapeutics is ...
TG Therapeutics announced presentations of new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers meeting. Data from the ongoing ENABLE Phase 4 study show significant patient-repor...
